Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program.
Kusejko K, Salazar-Vizcaya L, Shah C, Stöckle M, Béguelin C, Schmid P, Ongaro M, Darling K, Bernasconi E, Rauch A, Kouyos RD, Günthard HF, Böni J, Fehr JS, Braun DL; Swiss HIV Cohort Study. Kusejko K, et al. Among authors: schmid p. Clin Infect Dis. 2022 Nov 14;75(10):1723-1731. doi: 10.1093/cid/ciac273. Clin Infect Dis. 2022. PMID: 35404384 Free article.
Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.
Béguelin C, Moradpour D, Sahli R, Suter-Riniker F, Lüthi A, Cavassini M, Günthard HF, Battegay M, Bernasconi E, Schmid P, Calmy A, Braun DL, Furrer H, Rauch A, Wandeler G; Swiss HIV Cohort Study. Béguelin C, et al. Among authors: schmid p. J Hepatol. 2017 Feb;66(2):297-303. doi: 10.1016/j.jhep.2016.10.007. Epub 2016 Oct 14. J Hepatol. 2017. PMID: 27746337
Human papillomavirus antibody response following HAART initiation among MSM.
Combes JD, Clifford GM, Egger M, Cavassini M, Hirsch HH, Hauser C, Calmy A, Schmid P, Bernasconi E, Günthard HF, Franceschi S, Waterboer T, Scherrer AU; Swiss HIV Cohort Study. Combes JD, et al. Among authors: schmid p. AIDS. 2017 Feb 20;31(4):561-569. doi: 10.1097/QAD.0000000000001354. AIDS. 2017. PMID: 28121669 Free article.
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.
Béguelin C, Friolet N, Moradpour D, Sahli R, Suter-Riniker F, Lüthi A, Cavassini M, Günthard HF, Battegay M, Bernasconi E, Schmid P, Calmy A, Atkinson A, Rauch A, Wandeler G; Swiss HIV Cohort Study. Béguelin C, et al. Among authors: schmid p. Clin Infect Dis. 2017 May 1;64(9):1275-1278. doi: 10.1093/cid/cix125. Clin Infect Dis. 2017. PMID: 28199492 Free article.
Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort.
Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P, Schmid P, Orkin C, Pedersen C, Leen C, Pradier C, Mulcahy F, Ridolfo AL, Staub T, Maltez F, Weber R, Flamholc L, Kyselyova G, Lundgren JD, Mocroft A; for EuroSIDA. Borges ÁH, et al. Among authors: schmid p. Clin Infect Dis. 2017 May 15;64(10):1413-1421. doi: 10.1093/cid/cix167. Clin Infect Dis. 2017. PMID: 28329090
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Sculier D, Gayet-Ageron A, Battegay M, Cavassini M, Fehr J, Hirzel C, Schmid P, Bernasconi E, Calmy A; Swiss HIV Cohort Study. Sculier D, et al. Among authors: schmid p. BMC Infect Dis. 2017 Jul 6;17(1):476. doi: 10.1186/s12879-017-2579-2. BMC Infect Dis. 2017. PMID: 28683720 Free PMC article. Clinical Trial.
Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity.
Bertels F, Marzel A, Leventhal G, Mitov V, Fellay J, Günthard HF, Böni J, Yerly S, Klimkait T, Aubert V, Battegay M, Rauch A, Cavassini M, Calmy A, Bernasconi E, Schmid P, Scherrer AU, Müller V, Bonhoeffer S, Kouyos R, Regoes RR; Swiss HIV Cohort Study. Bertels F, et al. Among authors: schmid p. Mol Biol Evol. 2018 Jan 1;35(1):27-37. doi: 10.1093/molbev/msx246. Mol Biol Evol. 2018. PMID: 29029206 Free PMC article.
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
Bruggmann P, Blach S, Deltenre P, Fehr J, Kouyos R, Lavanchy D, Müllhaupt B, Rauch A, Razavi H, Schmid P, Semela D, Stoeckle M, Negro F. Bruggmann P, et al. Among authors: schmid p. Swiss Med Wkly. 2017 Nov 8;147:w14543. doi: 10.4414/smw.2017.14543. eCollection 2017. Swiss Med Wkly. 2017. PMID: 29120012 Free article.
1,478 results